~~<i id='0E98E83454'><strike id='0E98E83454'><tt id='0E98E83454'><pre id='0E98E83454'></pre></tt></strike></i>~~

Home» focus» hotspot

hotspot

author：hotspot 2025-10-02 06:28:32 Page View：5595

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The creative science of coining drug names
Next article： Continuity nursing helped my family in our darkest PICU moments

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

As billionaires fund anti

Metformin,adrugthatwasapprovedinthe’90sfortreatingdiabetes,wasshowninepidemiologicalstudiestoprevent

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

PBM executives asked to testify by House panel

Rep.JamesComer(R-Ky.),thechairoftheHouseCommitteeonOversightandAccountability,hastakenaninterestinph